The Ellisen laboratory studies fundamental mechanisms of tumorigenesis and their associated therapeutic implications in breast and other cancers. Topics of major interest include the p53 family of transcription factors, hereditary breast cancer and molecular genetics.
We have identified fundamental mechanisms of the p53 family members in tumorigenesis (Cancer Cell 2017; 31:35) and normal development (Dev Cell 2014; 30:151), and have discovered novel genetic breast cancer drivers (Cancer Discovery 2018).
We recently uncovered a new stress-induced tumor suppressor pathway involving regulation of mTOR activity (Nat Comm 2015; 6:7014), and revealed for the first time frequent gene regulatory mutations in breast cancer (Nature 2017; 547:55).
Our ability to work at the interface of basic tumor biology, genetics and therapeutic application is strongly supported by the research and clinical infrastructure of the MGH Cancer Center.
The position provides a rich intellectual environment with full integration into the large research communities of the Mass General and Harvard.
The candidate must have recently received a Ph.D. degree in the biological sciences, and be highly motivated and well versed in basic molecular biology and biochemical techniques. Previous publication in the English-language literature is essential.
The candidate must have recently received a Ph.D. degree in the biological sciences, and be highly motivated and well versed in basic molecular biology and biochemical techniques. Previous publication in the English-language
Massachusetts General Hospital is an Equal Opportunity Employer. By embracing diverse skills, perspectives and ideas, we choose to lead. Applications from protected veterans and individuals with disabilities are strongly encouraged.